Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Operating Cash Flow
Cash generated by the company's core business operations during the period.
Maze Therapeutics, Inc.NASDAQ: MAZE
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $39.11M (cash outflow) rose 32.5% year over year, ahead of the -273.9% change in trailing-twelve-month operating cash flow. Sequentially, it rose 41.0% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.
Context
- Operating cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +32.5% holds above the trailing-twelve-month pace of -273.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (111.94M) USD
- Year-over-year change
- -247.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (111.94M) | -247.4% |
| FY2024 | 2024-12-31 | 75.95M | +187.5% |
| FY2023 | 2023-12-31 | (86.83M) | +12.5% |
| FY2022 | 2022-12-31 | (99.2M) | — |
Operating Cash Flow vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -273.9% is the lowest of 8, against a peer median of +17.5%.
- Operating cash flow amounts to 607.7% of revenue for MAZE, versus a peer median of 51.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $153.09M USD | +361.2% | — | 23.5% | |
| LTM Mar 2026 | $121.54M USD | -273.9% | +4.1% | 607.7% | |
| FY2025 | €100.98M EUR | +17.5% | +31.0% | 2252.6% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $88.31M USD | +66.0% | +31.2% | 856.0% |
SEPNSepterna, Inc. | LTM Sep 2026 | $76.57M USD | -173.5% | — | 79.5% |
| LTM Mar 2026 | $36.26M USD | -23.7% | -15.4% | 8.5% | |
| LTM Mar 2026 | $31.05M USD | +37.6% | +36.2% | — | |
| LTM Jun 2026 | $30.5M USD | -104.3% | — | 3.0% | |
| Peer median (excluding MAZE) | — | +17.5% | +31.1% | 51.5% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.